Article
Gastroenterology & Hepatology
Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Summary: In this study, infliximab and adalimumab showed similar treatment efficacy and long-term outcomes in biologic-naive patients with moderate to severe UC. The analysis revealed that an elevated C-reactive protein level (>5 mg/L) was a significant predictive factor for poor outcomes in these patients.
Article
Biochemistry & Molecular Biology
Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Luisa Leite Barros, Jane Oba, Carlos Walter Sobrado Junior, Aytan Miranda Sipahi, Olivia Duarte de Castro Alves, Tomas Navarro-Rodriguez, Rogerio Serafim Parra, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Cristina Flores, Andrea Vieira, Christianne Damasceno Arcelino do Ceara, Natalia Sousa Freitas Queiroz, Aderson Omar Mourao Cintra Damiao
Summary: Therapeutic drug monitoring (TDM) is important in optimizing response to anti-tumor necrosis factor drugs and preventing inadequate drug exposure. This study aimed to describe the remission rates of Brazilian inflammatory bowel disease (IBD) patients at six months using a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels. The results showed that proactive TDM was associated with a high persistence rate of 82.9% and favorable remission rates at six months.
Article
Pharmacology & Pharmacy
Xavier Cortes, Joaquin Borras-Blasco, Laura Flor, Beatriz Antequera, Sergio Fernandez-Martinez, Jose Ramon Moles, Elvira Castera
Summary: In this case report, a 60-year-old man with ulcerative colitis refractory to azathioprine, infliximab, and adalimumab achieved successful remission with golimumab therapy. The patient showed significant improvement and sustained remission after switching to golimumab treatment, suggesting that golimumab may be an effective option for patients who do not respond to infliximab and adalimumab. Further studies are needed to confirm the efficacy of golimumab as a rescue treatment for refractory ulcerative colitis.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
Summary: The study demonstrated that golimumab was effective and safe as an induction and maintenance treatment for Korean patients with moderate-to-severe UC. Clinical response and remission rates increased over time, with a mucosal healing rate of 65.8%.
Review
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jorgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukas, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya
Summary: This study compared the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. The results showed that infliximab had better efficacy during the induction phase and comparable efficacy during the maintenance phase compared to vedolizumab. In terms of safety, there were no significant differences between the two treatments.
BMC GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, John K. Marshall, Jean-Frederic Colombel, Parambir S. Dulai, Walter Reinisch
Summary: For patients with moderate to severe biologic naive UC, infliximab and vedolizumab have similar efficacy in improving clinical symptoms, but infliximab has higher rates of corticosteroid-free clinical remission (CR) and endoscopic remission (ER) after 1 year of treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Claire T. Deakin, Bianca L. De Stavola, Geoffrey Littlejohn, Hedley Griffiths, Sabina Ciciriello, Peter Youssef, David Mathers, Paul Bird, Tegan Smith, Catherine O'Sullivan, Tim Freeman, Dana Segelov, David Hoffman, Shaun R. Seaman
Summary: This study compared the effectiveness of adalimumab and tofacitinib in patients with rheumatoid arthritis using the target trial emulation framework. The results showed that there was a small but significant reduction in DAS28-CRP at 3 months with tofacitinib compared to adalimumab, but no difference between the two treatments at 9 months.
Review
Gastroenterology & Hepatology
Eun Sil Kim, Ben Kang
Summary: The selection of biologic agents for pediatric Crohn's disease should be done carefully, as currently only infliximab and adalimumab are approved for use in children. Lack of comparison trials in pediatric patients necessitates the extrapolation of adult data. From a pharmacokinetic perspective, infliximab may be more advantageous in high inflammatory burden, while adalimumab may be better in sustaining remission during maintenance phase. Factors such as clinical indications, disease behavior, efficacy, safety, immunogenicity, patient preference, and compliance should be considered when choosing anti-TNF therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Kunio Asonuma, Keiji Ozeki, Hajime Yamazaki, Shinji Okabayashi, Soh Okano, Ryo Ozaki, Nobuaki Nishimata, Hiroki Kiyohara, Naoki Ichinari, Taku Kobayashi, Masahiro Yamada, Mao Matsubayashi, Yoko Yokoyama, Shoko Arimitsu, Junji Umeno, Yoshinori Munetomo, Akira Andoh, Shinichiro Shinzaki, IBD Terakoya Grp
Summary: The use of immunomodulators after discontinuing anti-TNF-alpha antibody treatment was not significantly associated with relapse in patients with UC. Careful patient follow-up is necessary when discontinuing due to side effects or in younger patients at the time of discontinuation.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward Loftus, Elham Ostad-Saffari, Astrid Scalori, Young S. Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William J. Sandborn
Summary: This study evaluated the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-TNF agents. The results showed that etrolizumab significantly improved remission rates at week 14 compared to placebo, but there was no significant difference between the two groups in remission rates at week 66.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Medicine, General & Internal
Abel Botelho Quaresma, Fernanda da Silva Barbosa Barauna, Fabio Vieira Teixeira, Rogerio Saad-Hossne, Paulo Gustavo Kotze
Summary: Most studies have not shown increased complication rates after abdominal surgical procedures in UC patients with preoperative exposure to biologics. Further prospective studies are needed to better establish the impact of preoperative biologics on surgical complications in UC.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fumery
Summary: This study assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs). The results showed that switching from intravenous to subcutaneous infliximab was safe and well accepted, with a low risk of relapse in IBD patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Article
Gastroenterology & Hepatology
Lauranne A. A. P. Derikx, Heather W. Dolby, Nikolas Plevris, Laura Lucaciu, Caitlin S. Rees, Mathew Lyons, Spyros Siakavellas, Nathan Constantine-Cooke, Philip Jenkinson, Shanna Su, Claire O'Hare, Laura Kirckpatrick, Lynne M. Merchant, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, Charlie W. Lees
Summary: The study found that switching from the ADA originator to SB5 is effective and safe for patients with inflammatory bowel disease. Over 12 months of follow-up, most patients remained stable on SB5 treatment. The most frequently reported adverse event was injection site pain.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Summary: This study compared the efficacy of infliximab (IFX) and adalimumab (ADA) in healing CD-PAF. The results showed that the IFX group had better clinical response at 6 months and higher biologic persistence. In addition, the study supported the use of concomitant immunomodulator therapy for CD-PAF healing and remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Shintaro Akiyama, Jacob E. Ollech, Victoria Rai, Laura R. Glick, Yangtian Yi, Cindy Traboulsi, Joseph Runde, Russell D. Cohen, Kinga B. Skowron, Roger D. Hurst, Konstantin Umanskiy, Benjamin D. Shogan, Neil H. Hyman, Michele A. Rubin, Sushila R. Dalal, Atsushi Sakuraba, Joel Pekow, Eugene B. Chang, David T. Rubin
Summary: This study developed a new classification system for pouchitis based on the pattern of inflammation observed in pouches. It identified 7 different phenotypes and evaluated the contributing factors and prognosis of each phenotype. The study provides valuable insights for pouch management and future interventional studies.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Charles Muller, Akihiro Yamada, Sachie Ikegami, Haider Haider, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba
Summary: Serrated polyposis syndrome (SPS) is an underrecognized CRC predisposition syndrome with a higher risk of colorectal cancer, especially at the time of diagnosis. Early recognition, screening, and enhanced surveillance protocols are crucial in managing the elevated CRC risk in SPS patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Anthony Buisson, Lisa Cannon, Konstantin Umanskiy, Roger D. Hurst, Neil H. Hyman, Atsushi Sakuraba, Joel Pekow, Sushila Dalal, Russell D. Cohen, Bruno Pereira, David T. Rubin
Summary: Anti-TNF therapy was found to be the most effective medication in preventing endoscopic and clinical postoperative recurrence (POR) in Crohn's disease (CD). Combination therapy with anti-TNF agents and immunosuppressive drugs should be considered for patients previously exposed to anti-TNF before surgery.
INTESTINAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Matthew Peller, Rajesh N. Keswani, Atsushi Sakuraba, Dejan Micic
Summary: The study found that a history of bariatric surgery is a risk factor for inadequate bowel preparation, particularly in patients who have undergone bypass surgery. Therefore, further efforts should be made to identify the appropriate bowel preparation regimen for these patients.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Gastroenterology & Hepatology
Atsushi Sakuraba, Alexander Luna, Dejan Micic
Summary: The meta-analysis showed that patients with immune-mediated inflammatory diseases have a reduced response to mRNA COVID-19 vaccines, especially those receiving anti-CD20 and anti-tumor necrosis factor therapy. These patients are less likely to achieve a serologic response even after completing the full vaccine series.
Review
Oncology
Atsushi Sakuraba, Alexander Luna, Dejan Micic
Summary: Patients with cancer, especially those with hematologic B-cell malignancies, have a lower serologic response to COVID-19 vaccines. Additional strategies for prophylaxis should be considered for cancer patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Gastroenterology & Hepatology
Fares Ayoub, Matthew Odenwald, Dejan Micic, Sushila R. Dalal, Joel Pekow, Russell D. Cohen, David T. Rubin, Atsushi Sakuraba
Summary: This article systematically reviewed the effectiveness of vedolizumab for the management of perianal fistulizing CD and conducted a meta-analysis. The results showed that vedolizumab treatment led to healing of perianal fistulas in nearly one-third of the 198 patients included in the study. However, the lack of high-quality data and significant study heterogeneity highlight the need for future prospective studies to evaluate fistula healing in patients receiving anti-integrin therapy.
INTESTINAL RESEARCH
(2022)
Article
Medicine, General & Internal
Nathaniel A. Cohen, Dejan M. Micic, Atsushi Sakuraba
Summary: In this study, mental health disorders and smoking were independently associated with non-compliance to medication in predominantly adolescent, hospitalized pediatric CD patients. A multidisciplinary approach involving pediatric gastroenterologists, psychiatrists, and addiction specialists is needed to treat the underlying causes and improve adherence in these patients.
ANNALS OF MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Shintaro Akiyama, Jacob E. Ollech, Cindy Traboulsi, Victoria Rai, Laura R. Glick, Yangtian Yi, Joseph Runde, Andrea D. Olivas, Christopher R. Weber, Russell D. Cohen, Kinga B. Skowron Olortegui, Roger D. Hurst, Konstantin Umanskiy, Benjamin D. Shogan, Michele A. Rubin, Sushila R. Dalal, Atsushi Sakuraba, Joel Pekow, Eugene B. Chang, John Hart, Neil H. Hyman, David T. Rubin
Summary: Our study aimed to assess how the histopathology of colectomy specimens predicts endoscopic pouch phenotypes in patients with UC. The results showed that deep inflammation was significantly associated with pouch fistulas, while terminal ileal involvement significantly increased the risk of afferent limb involvement.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Virology
Atsushi Sakuraba, Alexander Luna, Dejan Micic
Summary: The serologic response to the COVID-19 vaccine is extremely low in solid organ transplant recipients, and even the third dose has an insufficient response. Strategies for prophylaxis need to be developed for this vulnerable patient population.
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Maryam Zafer, Hui Zhang, Sujaata Dwadasi, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D. Cohen, Joel Pekow, David T. Rubin, Atsushi Sakuraba, Dejan Micic
Summary: The predictive factors for colectomy in severe ulcerative colitis include prior biologic exposure, need for inpatient salvage therapy, and younger age. A clinical predictive model based on admission data was developed to identify high-risk patients for one-year colectomy in adults hospitalized for severe UC.
CROHNS & COLITIS 360
(2022)
